Michele Dal Bo

Suggest Changes
Learn More
BACKGROUND TP53 defects, i.e., 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct(More)